Monitor the ALPHA3 trial data readout and any pipeline updates under the new CEO. The transition is orderly and internal, suggesting continuity — no immediate trading catalyst.
Price Chart
Executive Summary
Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective June 30, 2026, and will be succeeded by Dr. Zachary Roberts, the current EVP of R&D and CMO, effective July 1, 2026. This is a routine leadership succession event with no material financial impact — the company remains on its existing clinical development path.
Key Facts
- Dr. David Chang to transition from President and CEO effective June 30, 2026, after eight years of leadership.
- Dr. Zachary Roberts, EVP of R&D and CMO, appointed President and CEO effective July 1, 2026, and to the Board.
- Dr. Chang will continue to serve on the Board of Directors.
- Dr. Roberts joined Allogene in January 2023 and led the design of the pivotal ALPHA3 trial in first-line LBCL.
- No financial terms, severance, or compensation changes were disclosed in the press release.
Financial Impact
No financial impact disclosed — leadership transition is routine and planned.
Risk Factors
- Potential strategic shift under new CEO, though Dr. Roberts was already leading R&D.
- No financial details provided — any undisclosed compensation or severance could emerge in subsequent filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303320 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.21 (−3.20%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.21 (−38.89%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.21 (−40.39%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.21 (+42.11%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.21 (−38.58%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.21 (−44.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers